1-pentyl-1H-benzo[d]imidazol-2-amine | 866100-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-pentyl-1H-benzo[d]imidazol-2-amine
• 英文别名: 1-Pentylbenzimidazol-2-amine
• CAS: 866100-36-9
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.287
• InChiKey: ZKATYZMBJKQQKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对氯苯乙酸 、 1-pentyl-1H-benzo[d]imidazol-2-amine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以95%的产率得到2-(4-chlorophenyl)-N-(1-pentyl-1H-benzo[d]imidazol-2-yl)acetamide
  参考文献：
  名称：

  新型苯并咪唑苯基乙酰胺作为广谱锥虫的全过程优化

  摘要：

  克鲁氏锥虫和布鲁氏锥虫分别是恰加斯氏病和人类非洲锥虫病（HAT）的寄生病原体。当前用于治疗这些疾病的药物对于所有阶段和/或寄生虫亚种并不是有效的，经常表现出副作用。本文中，我们报告了先前从高通量筛选中发现的针对T. cruzi，布鲁氏锥虫的新型命中的2-（4-氯苯基）-N-（1-丙基-1 H-苯并咪唑-2-基）乙酰胺的SAR探索。布鲁西和利什曼原虫。合成了一组信息丰富的类似物，其中掺入了支架的关键修饰，从而提高了效力，而大多数化合物对H9c2和HEK293细胞系保留了低细胞毒性。针对克氏锥虫观察到的SAR与针对Tb brucei观察到的SAR大致相同，这表明有可能使用广谱候选物。因此，这类化合物值得进一步研究以开发作为南美锥虫病和HAT的治疗药物。

  DOI：

  10.1039/d0md00058b
• 作为产物：
  描述：

  邻苯二胺 在 potassium hydroxide 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 6.0h， 生成 1-pentyl-1H-benzo[d]imidazol-2-amine
  参考文献：
  名称：

  Human Toll-Like Receptor 8-Selective Agonistic Activities in 1-Alkyl-1H-benzimidazol-2-amines

  摘要：

  Toll-like receptor (TLR)-8 agonists strongly induce the production of T helper 1-polarizing cytokines and may therefore serve as promising candidate vaccine adjuvants, especially for the very young and the elderly. Earlier structure-based ligand design led to the identification of 3-pentyl-quinoline-2-amine as a novel, human TLR8-specific agonist. Comprehensive structure-activity relationships in ring-contracted 1-alkyl-1H-benzimidazol-2-amines were undertaken, and the best-in-class compound, 4-methyl-1-pentyl-1H-benzo[d]imidazol-2-amine, was found to be a pure TLR8 agonist, evoking strong proinflammatory cytokine and Type II interferon responses in human PBMCs, with no attendant CD69 upregulation in natural lymphocytic subsets. The 1-alkyl-1H-benzimidazol-2-amines represent a novel, alternate chemotype with pure TLR8-agonistic activities and will likely prove useful not only in understanding TLR8 signaling but also perhaps as a candidate vaccine adjuvant.

  DOI：

  10.1021/jm500701q

文献信息

• [EN] DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS<br/>[FR] DIAMINO-PYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE L'ANGIOGENESE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003074515A1

  公开（公告）日：2003-09-12

  Benzimidazole derivatives of formula (I) , which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. (I)

  本发明描述了公式(I)的苯并咪唑衍生物，它们作为TIE-2和/或VEGFR-2抑制剂是有用的。所描述的发明还包括制造这样的苯并咪唑衍生物的方法，以及使用它们在治疗增生性疾病中的方法。
• [EN] TOLL-LIKE RECEPTOR AGONISTS<br/>[FR] AGONISTES DE RÉCEPTEURS DE TYPE TOLL
  申请人：UNIV KANSAS

  公开号：WO2015023958A1

  公开（公告）日：2015-02-19

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivatives thereof, prodrugs thereof, salts thereof, or stereoisomers thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines, as well as for other therapeutic purposes described herein.

  本文描述的化合物可用于治疗目的。这些化合物可以是TLR激动剂，例如TLR7或TLR8激动剂。这些化合物可以包含在药物组合物中，并用于需要作为TLR激动剂有用的治疗中。药物组合物可以包括任何成分，如载体、稀释剂、赋形剂、填料或类似的在药物组合物中常见的成分。这些化合物可以是本文所示或描述的化合物，以及其衍生物、前药、盐、立体异构体，或在任何手性中心具有任何手性，或互变异构体、多晶形、溶剂化合物，或其组合。因此，这些化合物可以用作疫苗的佐剂，以及用于本文描述的其他治疗目的。
• THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
  申请人：Northwestern University

  公开号：US20170305901A1

  公开（公告）日：2017-10-26

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  揭示了治疗与混合系谱白血病基因（MLL-r）重排相关的癌症的方法，包括MLL-r白血病。这些方法通常包括给予治疗量的一个或多个治疗剂，其抑制白介素-1信号通路的一个或多个成员的生物活性，例如白介素-1受体相关激酶4（IRAK4）的抑制剂。
• Diamino-pyrimidines and their use as angiogenesis inhibitors
  申请人：Chamberlain Dawes Stanley

  公开号：US20050234083A1

  公开（公告）日：2005-10-20

  Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为TIE-2和/或VEGFR-2抑制剂有用的苯并咪唑衍生物。所述发明还包括制备这种苯并咪唑衍生物的方法，以及将其用于治疗过度增殖性疾病的方法。
• Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels
  申请人：Sorensen Ulrik Svane

  公开号：US20080200529A1

  公开（公告）日：2008-08-21

  This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及一种新型2-氨基苯并咪唑衍生物，可用作小通量钙激活钾通道（SK通道）的调节剂。在其他方面，本发明涉及将这些化合物用于治疗方法以及包含本发明化合物的制药组合物。